197 related articles for article (PubMed ID: 36284117)
1. Ramucirumab combination with sorafenib enhances the inhibitory effect of sorafenib on HepG2 cancer cells.
Taha AM; Aboulwafa MM; Zedan H; Helmy OM
Sci Rep; 2022 Oct; 12(1):17889. PubMed ID: 36284117
[TBL] [Abstract][Full Text] [Related]
2. Antitumor effects of rhamnazinon sorafenib-treated human hepatocellular carcinoma cell lines via modulation of VEGF signaling and PI3K/NF-κB p38/caspase-3 axes cross talk.
Habiba YH; Omran GA; Helmy MW; Houssen ME
Life Sci; 2022 May; 297():120443. PubMed ID: 35245519
[TBL] [Abstract][Full Text] [Related]
3. Fucoidan inhibits EGFR redistribution and potentiates sorafenib to overcome sorafenib-resistant hepatocellular carcinoma.
Luo J; Li L; Zhu Z; Chang B; Deng F; Wang D; Lu X; Zuo D; Chen Q; Zhou J
Biomed Pharmacother; 2022 Oct; 154():113602. PubMed ID: 36029544
[TBL] [Abstract][Full Text] [Related]
4. Metformin Enhances the Anti-Cancer Efficacy of Sorafenib via Suppressing MAPK/ERK/Stat3 Axis in Hepatocellular Carcinoma.
Siddharth S; Kuppusamy P; Wu Q; Nagalingam A; Saxena NK; Sharma D
Int J Mol Sci; 2022 Jul; 23(15):. PubMed ID: 35897659
[TBL] [Abstract][Full Text] [Related]
5. MiRNA153 Reduces Effects of Chemotherapeutic Agents or Small Molecular Kinase Inhibitor in HCC Cells.
Chen Y; Feng F; Gao X; Wang C; Sun H; Zhang C; Zeng Z; Lu Y; An L; Qu J; Wang F; Yang Y
Curr Cancer Drug Targets; 2015; 15(3):176-87. PubMed ID: 25714700
[TBL] [Abstract][Full Text] [Related]
6. Validation of VX2 as a Hepatocellular Carcinoma Model: Comparison of the Molecular Reaction of VX2 and HepG2 Tumor Cells to Sorafenib In Vitro.
Nass N; Streit S; Wybranski C; Jürgens J; Brauner J; Schulz N; Powerski M; Ricke J; Kalinski T; Dudeck O; Seidensticker M
Anticancer Res; 2017 Jan; 37(1):87-93. PubMed ID: 28011478
[TBL] [Abstract][Full Text] [Related]
7. 1118-20, an indazole diarylurea compound, inhibits hepatocellular carcinoma HepG2 proliferation and tumour angiogenesis involving Wnt/β-catenin pathway and receptor tyrosine kinases.
Lu YY; Wang JJ; Zhang XK; Li WB; Guo XL
J Pharm Pharmacol; 2015 Oct; 67(10):1393-405. PubMed ID: 26076716
[TBL] [Abstract][Full Text] [Related]
8. miR‑222 regulates sorafenib resistance and enhance tumorigenicity in hepatocellular carcinoma.
Liu K; Liu S; Zhang W; Ji B; Wang Y; Liu Y
Int J Oncol; 2014 Oct; 45(4):1537-46. PubMed ID: 25096647
[TBL] [Abstract][Full Text] [Related]
9. Autocrine vascular endothelial growth factor signaling promotes cell proliferation and modulates sorafenib treatment efficacy in hepatocellular carcinoma.
Peng S; Wang Y; Peng H; Chen D; Shen S; Peng B; Chen M; Lencioni R; Kuang M
Hepatology; 2014 Oct; 60(4):1264-77. PubMed ID: 24849467
[TBL] [Abstract][Full Text] [Related]
10. Sorafenib inhibits proliferation and invasion of human hepatocellular carcinoma cells via up-regulation of p53 and suppressing FoxM1.
Wei JC; Meng FD; Qu K; Wang ZX; Wu QF; Zhang LQ; Pang Q; Liu C
Acta Pharmacol Sin; 2015 Feb; 36(2):241-51. PubMed ID: 25557114
[TBL] [Abstract][Full Text] [Related]
11. [Coadministration of sorafenib and cisplatin inhibits proliferation of hepatocellular carcinoma HepG2 cells in vitro].
Chen FS; Cui YZ; Luo RC; Wu J; Zhang H
Nan Fang Yi Ke Da Xue Xue Bao; 2008 Aug; 28(9):1684-7. PubMed ID: 18819900
[TBL] [Abstract][Full Text] [Related]
12. Inhibition of MMP-2 Expression Enhances the Antitumor Effect of Sorafenib in Hepatocellular Carcinoma by Suppressing the PI3K/AKT/mTOR Pathway.
Tan W; Zhu S; Cao J; Zhang L; Li W; Liu K; Zhong J; Shang C; Chen Y
Oncol Res; 2017 Nov; 25(9):1543-1553. PubMed ID: 28276313
[TBL] [Abstract][Full Text] [Related]
13. Combination therapy of sorafenib with mesenchymal stem cells as a novel cancer treatment regimen in xenograft models of hepatocellular carcinoma.
Seyhoun I; Hajighasemlou S; Muhammadnejad S; Ai J; Nikbakht M; Alizadeh AA; Hosseinzadeh F; Mirmoghtadaei M; Seyhoun SM; Verdi J
J Cell Physiol; 2019 Jun; 234(6):9495-9503. PubMed ID: 30362607
[TBL] [Abstract][Full Text] [Related]
14. Synergistic anticancer effect of flavonoids from Sophora alopecuroides with Sorafenib against hepatocellular carcinoma.
Zhu XF; Sun ZL; Ma J; Hu B; Yu MC; Liu XJ; Yang P; Xu Y; Ju D; Mu Q
Phytother Res; 2023 Feb; 37(2):592-610. PubMed ID: 36180975
[TBL] [Abstract][Full Text] [Related]
15. Cyclin E1 Inhibition can Overcome Sorafenib Resistance in Hepatocellular Carcinoma Cells Through Mcl-1 Suppression.
Hsu C; Lin LI; Cheng YC; Feng ZR; Shao YY; Cheng AL; Ou DL
Clin Cancer Res; 2016 May; 22(10):2555-64. PubMed ID: 26603262
[TBL] [Abstract][Full Text] [Related]
16. Single Agent and Synergistic Activity of the "First-in-Class" Dual PI3K/BRD4 Inhibitor SF1126 with Sorafenib in Hepatocellular Carcinoma.
Singh AR; Joshi S; Burgoyne AM; Sicklick JK; Ikeda S; Kono Y; Garlich JR; Morales GA; Durden DL
Mol Cancer Ther; 2016 Nov; 15(11):2553-2562. PubMed ID: 27496136
[TBL] [Abstract][Full Text] [Related]
17. Sorafenib enhances proteasome inhibitor-induced cell death via inactivation of Akt and stress-activated protein kinases.
Honma Y; Shimizu S; Takehara T; Harada M
J Gastroenterol; 2014 Mar; 49(3):517-26. PubMed ID: 23543326
[TBL] [Abstract][Full Text] [Related]
18. Sorafenib inhibits migration and invasion of hepatocellular carcinoma cells through suppression of matrix metalloproteinase expression.
Ha TY; Hwang S; Moon KM; Won YJ; Song GW; Kim N; Tak E; Ryoo BY; Hong HN
Anticancer Res; 2015 Apr; 35(4):1967-76. PubMed ID: 25862849
[TBL] [Abstract][Full Text] [Related]
19. Novel combination of sorafenib and biochanin-A synergistically enhances the anti-proliferative and pro-apoptotic effects on hepatocellular carcinoma cells.
Youssef MM; Tolba MF; Badawy NN; Liu AW; El-Ahwany E; Khalifa AE; Zada S; Abdel-Naim AB
Sci Rep; 2016 Jul; 6():30717. PubMed ID: 27470322
[TBL] [Abstract][Full Text] [Related]
20. Differential effects of arsenic trioxide on chemosensitization in human hepatic tumor and stellate cell lines.
Rangwala F; Williams KP; Smith GR; Thomas Z; Allensworth JL; Lyerly HK; Diehl AM; Morse MA; Devi GR
BMC Cancer; 2012 Sep; 12():402. PubMed ID: 22963400
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
